Biblio Discovery — Demo Discovery Service

12 results for "Meir Schechter"

Showing 1–12 · 2.74 seconds · RSS

  1. Journal Article

    An Emerging Role for Phosphoinositides in the Pathophysiology of Parkinson’s Disease

    Meir Schechter; Ronit Sharon

    Journal of Parkinson’s Disease, Vol. 11 · 2021 · English · DOAJ Scopus

    Recent data support an involvement of defects in homeostasis of phosphoinositides (PIPs) in the pathophysiology of Parkinson’s disease (PD). Genetic mutations have been identified in genes encoding for PIP-regulating and PIP-interacting proteins, that are associated with familial and sporadic PD…

  2. Journal Article Full text

    Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains

    Jessica Grigoletto; Meir Schechter; Ronit Sharon

    Life, Vol. 12 No. 1 · 2022 · English · DOAJ Scopus

    Ultrastructural, neurochemical, and molecular alterations within the striatum are associated with the onset and progression of Parkinson’s disease (PD). In PD, the dopamine-containing neurons in the substantia nigra pars compacta (SNc) degenerate and reduce dopamine-containing innervations to the…

  3. Journal Article

    Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers

    Sok Cin Tye; Sieta T. de Vries; Johannes F. E. Mann et al.

    Frontiers in Pharmacology, Vol. 13 · 2022 · English · DOAJ Scopus

    Aims: The LEADER trial demonstrated that the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide reduces kidney and cardiovascular (CV) risk in patients with type 2 diabetes. We previously developed a Parameter Response Efficacy (PRE) score that translates multiple short-term risk marker…

  4. Journal Article

    α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription

    Dana Davidi; Meir Schechter; Suaad Abd Elhadi et al.

    iScience, Vol. 23 No. 3 · 2020 · English · DOAJ Scopus

    Summary: α-Synuclein (α-Syn) protein is implicated in the pathogenesis of Parkinson disease (PD). It is primarily cytosolic and interacts with cell membranes. α-Syn also occurs in the nucleus. Here we investigated the mechanisms involved in nuclear translocation of α-Syn. We analyzed alterations in…

  5. Journal Article

    Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

    Meir Schechter; Cheli Melzer-Cohen; Aliza Rozenberg et al.

    Cardiovascular Diabetology, Vol. 20 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of these benefits also in lower kidney-risk T2D…

  6. Journal Article

    From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes

    Ofri Mosenzon; Stefano Del Prato; Meir Schechter et al.

    Cardiovascular Diabetology, Vol. 20 No. 1 · 2021 · English · DOAJ Scopus

    Abstract During the last decade we experienced a surge in the number of glucose lowering agents that can be used to treat patients with type 2 diabetes. Especially important are the discoveries that sodium glucose co-transporter type 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor…

  7. Journal Article

    Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study

    Meir Schechter; Alisa Fishkin; Ofri Mosenzon et al.

    Cardiovascular Diabetology, Vol. 24 No. 1 · 2025 · English · DOAJ Scopus

    Abstract Background Type 2 diabetes (T2D), affecting approximately 12% of the global population and over 30% of older adults, is among the most prevalent and fast-growing risk factors for neurodegenerative disorders. Evidence is lacking on whether specific glucose-lowering agents may reduce the…

  8. Journal Article

    A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson’s disease

    Meir Schechter; Jessica Grigoletto; Suaad Abd-Elhadi et al.

    Molecular Neurodegeneration, Vol. 15 No. 1 · 2020 · English · DOAJ Scopus

    Abstract Background α-Synuclein (α-Syn) is a protein implicated in the pathogenesis of Parkinson’s disease (PD). α-Syn has been shown to associate with membranes and bind acidic phospholipids. However, the physiological importance of these associations to the integrity of axons is not fully clear…

  9. Journal Article

    Dementia progression with GLP‐1 receptor agonists in people with mild cognitive impairment and type 2 diabetes: target‐trial emulation study

    Meir Schechter; Dvora R Sehtman‐Shachar; Alisa Fishkin et al.

    Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol. 12 No. 3 · 2026 · English · DOAJ Scopus

    Abstract INTRODUCTION In people with type 2 diabetes (T2D) without dementia, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) improved cardiovascular, kidney, and mortality outcomes, with multiple real‐world studies suggesting reduced risk of dementia onset. However, the EVOKE/EVOKE+…

  10. Journal Article

    Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults

    Meir Schechter; Cheli Melzer Cohen; Ilan Yanuv et al.

    Cardiovascular Diabetology, Vol. 21 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background Type-2 diabetes (T2D), chronic kidney disease, and heart failure (HF) share epidemiological and pathophysiological features. Although their prevalence was described, there is limited contemporary, high-resolution, epidemiological data regarding the overlap among them. We aimed…

  11. Journal Article

    Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence

    Meir Schechter; Cheli Melzer Cohen; Alisa Fishkin et al.

    Cardiovascular Diabetology, Vol. 22 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. However, limited data are available regarding the…

  12. Journal Article

    Incidence and clinical manifestations of sudden death in young adults: a two-decade, nationwide, retrospective, cross-sectional study

    Yair Maayan; Koral Yuhter; Hadasa Sarshevsky et al.

    Resuscitation Plus, Vol. 29 · 2026 · English · DOAJ Scopus

    Aim: Sudden death in healthy young adults is a rare but devastating event, and its causes and clinical features are not well understood. We describe the clinical manifestations and causes of sudden death in a nationwide-representative cohort of young adults. Methods: All natural non-traumatic…